Details of the Drug Combination

General Information of Drug Combination (ID: DC75NC1)

• Drug Combination Name: Vemurafenib + Plicamycin
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  Vemurafenib (DM62UG5): Small molecular drug
  Plicamycin (DM7C8YV): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: SW-620
  Zero Interaction Potency (ZIP) Score: 29.38
  Bliss Independence Score: 23.55
  Loewe Additivity Score: 4.71
  LHighest Single Agent (HSA) Score: 4.71

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Vemurafenib

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Approved	[2]

Vemurafenib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Serine/threonine-protein kinase B-raf (BRAF)	TTWCGQT	BRAF_HUMAN	Modulator	[3]

Vemurafenib Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[9]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[9]

Vemurafenib Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[10]

Vemurafenib Interacts with 8 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Microphthalmia-associated transcription factor (MITF)	OT6XJCZH	MITF_HUMAN	Affects Expression	[6]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[11]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Increases Expression	[12]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Phosphorylation	[7]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Phosphorylation	[7]
CD70 antigen (CD70)	OTHB2AL1	CD70_HUMAN	Decreases Expression	[13]
Melanocyte protein PMEL (PMEL)	OTCDDHHM	PMEL_HUMAN	Increases Expression	[6]
Melanoma antigen recognized by T-cells 1 (MLANA)	OT1N2S2K	MAR1_HUMAN	Increases Expression	[6]

Indication(s) of Plicamycin

Disease Entry	ICD 11	Status	REF
Hypercalcaemia	5B91.0	Approved	[3]
Testicular cancer	2C80	Approved	[3]
Solid tumour/cancer	2A00-2F9Z	Withdrawn from market	[4]
Lung cancer	2C25.0	Investigative	[5]
Ovarian cancer	2C73	Investigative	[5]

Plicamycin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
RNA synthesis (hRNA synth)	TTX2AYW	NOUNIPROTAC	Modulator	[15]

Plicamycin Interacts with 8 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)	OT3K7HY5	DHB2_HUMAN	Decreases Expression	[16]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[17]
Proto-oncogene tyrosine-protein kinase Src (SRC)	OTETYX40	SRC_HUMAN	Decreases Expression	[18]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Decreases Expression	[19]
Transcription factor Sp3 (SP3)	OTYDQZ1T	SP3_HUMAN	Decreases Expression	[14]
Epidermal growth factor receptor kinase substrate 8 (EPS8)	OTZ6ES6V	EPS8_HUMAN	Decreases Expression	[18]
TNFAIP3-interacting protein 1 (TNIP1)	OTRAOTEW	TNIP1_HUMAN	Decreases Expression	[20]
Sphingomyelin phosphodiesterase 3 (SMPD3)	OTHQBETH	NSMA2_HUMAN	Decreases Expression	[21]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Carcinoma	DC05WSL	RXF 393	Investigative	[22]
Carcinoma	DCWHHQN	MCF7	Investigative	[22]
Colon adenocarcinoma	DCH9FDL	COLO 205	Investigative	[22]
Colon carcinoma	DCF9N8A	KM12	Investigative	[22]
Invasive ductal carcinoma	DCX9W8B	BT-549	Investigative	[22]
Invasive ductal carcinoma	DCNLBE5	HS 578T	Investigative	[22]
Invasive ductal carcinoma	DCZTZ9E	T-47D	Investigative	[22]
Adenocarcinoma	DCKNOV8	DU-145	Investigative	[1]
Adenocarcinoma	DCWDJ7M	OVCAR3	Investigative	[1]
Adenocarcinoma	DCX4V28	NCIH23	Investigative	[1]
Adenocarcinoma	DC38VHF	A549	Investigative	[1]
Adenocarcinoma	DCNPD62	HT29	Investigative	[1]
Adenocarcinoma	DCQP8CV	HCT116	Investigative	[1]
Adult acute myeloid leukemia	DC4HP4E	HL-60(TB)	Investigative	[1]
Amelanotic melanoma	DC9IRHW	M14	Investigative	[1]
Amelanotic melanoma	DCPX94P	MDA-MB-435	Investigative	[1]
Anaplastic large cell lymphoma	DCPOKL4	SR	Investigative	[1]
Astrocytoma	DC6J564	SNB-19	Investigative	[1]
Childhood T acute lymphoblastic leukemia	DC4QSK0	CCRF-CEM	Investigative	[1]
Chronic myelogenous leukemia	DCXI08Y	K-562	Investigative	[1]
Clear cell renal cell carcinoma	DCYV3QO	786-0	Investigative	[1]
Clear cell renal cell carcinoma	DCA533J	A498	Investigative	[1]
Clear cell renal cell carcinoma	DCCMNUO	TK-10	Investigative	[1]
Clear cell renal cell carcinoma	DCNYD2H	CAKI-1	Investigative	[1]
Cutaneous melanoma	DCQT4Y1	SK-MEL-5	Investigative	[1]
Glioblastoma	DCAP0KL	SNB-75	Investigative	[1]
Glioma	DCS7X3S	SF-268	Investigative	[1]
Glioma	DC15OV4	SF-295	Investigative	[1]
Glioma	DC011S5	SF-539	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCQ1ZBC	OVCAR-8	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCKFN6S	OVCAR-5	Investigative	[1]
Large cell lung carcinoma	DCCYIUS	NCI-H460	Investigative	[1]
Lung adenocarcinoma	DCSKY2I	HOP-62	Investigative	[1]
Lung adenocarcinoma	DCQ8Z73	EKVX	Investigative	[1]
Lung adenocarcinoma	DCM0TGK	MDA-MB-231	Investigative	[1]
Lung adenocarcinoma	DC9WWA4	NCI-H522	Investigative	[1]
Malignant melanoma	DCQ0NHB	LOX IMVI	Investigative	[1]
Malignant melanoma	DCS9CG3	UACC62	Investigative	[1]
Melanoma	DCVQHZW	MALME-3M	Investigative	[1]
Melanoma	DC82YZ1	UACC-257	Investigative	[1]
Melanoma	DCOO583	SK-MEL-2	Investigative	[1]
Minimally invasive lung adenocarcinoma	DCRAZRU	NCI-H322M	Investigative	[1]
Mixed endometrioid and clear cell carcinoma	DC1IN24	IGROV1	Investigative	[1]
Non-small cell lung carcinoma	DCJAPNR	HOP-92	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCWG8IE	SK-OV-3	Investigative	[1]
Papillary renal cell carcinoma	DCT1WMY	ACHN	Investigative	[1]
Plasma cell myeloma	DCD3D9F	RPMI-8226	Investigative	[1]
Pleural epithelioid mesothelioma	DCSTHBE	NCI-H226	Investigative	[1]
Prostate carcinoma	DCZEDLB	PC-3	Investigative	[1]
Renal cell carcinoma	DCSCYQT	UO-31	Investigative	[1]
Renal cell carcinoma	DCFAJ2B	SN12C	Investigative	[1]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5893).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8394).
• [5] The Pluripotency Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy.Ann Am Thorac Soc. 2018 Apr;15(Supplement_2):S124.
• [6] PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. J Cancer. 2015 Oct 29;6(12):1320-30. doi: 10.7150/jca.11126. eCollection 2015.
• [7] Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J. 2016 Mar 1;35(5):462-78. doi: 10.15252/embj.201592081. Epub 2015 Dec 14.
• [8] Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. J Pharm Pharm Sci. 2014;17(1):154-68.
• [9] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [10] Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43.
• [11] Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. Elife. 2015 Aug 18;4:e04640. doi: 10.7554/eLife.04640.
• [12] Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016 Jan 26;7(4):4428-41. doi: 10.18632/oncotarget.6599.
• [13] Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity. PLoS One. 2016 Feb 1;11(2):e0148095. doi: 10.1371/journal.pone.0148095. eCollection 2016.
• [14] The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription. Chem Biol Interact. 2014 Aug 5;219:123-32. doi: 10.1016/j.cbi.2014.05.019. Epub 2014 Jun 4.
• [15] Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA. Biochemistry. 1995 Jan 31;34(4):1376-85.
• [16] SP1 and SP3 mediate progesterone-dependent induction of the 17beta hydroxysteroid dehydrogenase type 2 gene in human endometrium. Biol Reprod. 2006 Oct;75(4):605-14.
• [17] Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem. 2007 Jan 26;282(4):2615-25. doi: 10.1074/jbc.M606203200. Epub 2006 Nov 22.
• [18] Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact. 2010 Jan 5;183(1):181-6. doi: 10.1016/j.cbi.2009.09.018.
• [19] The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep. 2008 Jun;28(3):161-76. doi: 10.1042/BSR20080046.
• [20] Sp sites contribute to basal and inducible expression of the human TNIP1 (TNF-inducible protein 3-interacting protein 1) promoter. Biochem J. 2013 Jun 15;452(3):519-29. doi: 10.1042/BJ20121666.
• [21] Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009 Nov-Dec;1789(11-12):681-90. doi: 10.1016/j.bbagrm.2009.08.006. Epub 2009 Aug 19.
• [22] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165